IASLC releases interactive staging tool in thoracic oncology

The International Association for the Study of Lung Cancer (IASLC), the only global organization dedicated to the study of lung cancer, today announced the release of its Staging Atlas in Thoracic Oncology as a downloadable application for iPad, iPhone, Android or BlackBerry.

The app, which puts the most up-to-date TNM (tumor, node, metastasis) staging information in the hands of doctors and patients living with cancer, is available in English, French, German, Japanese, Italian, Spanish and Chinese.

The Staging Atlas was developed in collaboration with the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC). It's the first-ever site-specific guide on the TNM classification of thoracic malignancies. With its IASLC-original illustrations, beautifully rendered specifically for iPad and smartphone media, it serves as a complement to and enhancement of the AJCC and UICC staging publications.

This interactive staging tool for on-the-spot verification of the most up-to-date TNM classification variables is especially valuable to oncologists, surgeons, radiologists and scientists working in the field of thoracic oncology.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Stand Up To Cancer partners with Johnson & Johnson to explore new treatment for AL amyloidosis